Resveratrol

What Is Resveratrol?

Resveratrol is a polyphenol from the stilbene family, produced by plants as a defensive response to fungal infection, bacterial attack, and UV radiation. It is found primarily in the skin of red grapes, red wine, peanuts, and berries (blueberries, mulberries).

The compound gained scientific attention through two developments. First, it was proposed as a partial explanation for the so-called “French paradox” — the observation that France had relatively low coronary heart disease rates despite a high-fat diet, potentially linked to red wine consumption. This explanation has since been heavily contested. Second, Harvard researcher David Sinclair popularised resveratrol as a SIRT1 activator and caloric restriction mimetic in the mid-2000s, triggering a wave of commercial interest that remains active today.

Resveratrol in Food Sources

Mechanisms: Sirtuins and the Longevity Hypothesis

SIRT1 Activation

Resveratrol is best known for purportedly activating SIRT1, a NAD⁺-dependent deacetylase positioned as a key regulator of lifespan extension under caloric restriction. The mechanistic picture has grown more complicated since early reports:

• Direct activation: Early studies (Howitz et al. 2003) reported direct binding to SIRT1; these findings were subsequently criticised as artifacts of the fluorescence-based assay system used
• Indirect activation via AMPK: More recent data suggest resveratrol acts primarily through PDE4 inhibition → cAMP elevation → AMPK activation → SIRT1 deacetylation
• PGC-1α and mitochondrial biogenesis: In animal models, resveratrol increases mitochondrial density and oxidative capacity, consistent with caloric restriction mimicry

The Bioavailability Problem

Here lies the central limitation of oral resveratrol supplementation. Orally ingested resveratrol barely reaches systemic circulation at biologically active concentrations.

Walle et al. (PMID 25905295) characterised this in humans: after 25 mg oral administration, approximately 70% of resveratrol was absorbed from the gut — but underwent extensive first-pass metabolism (sulfation and glucuronidation in the intestinal wall and liver), rendering it almost entirely inactive. Bioavailability as free trans-resveratrol in plasma is <1%. Plasma half-life: approximately 2 hours.

Conjugated metabolites (sulfates and glucuronides) accumulate at higher concentrations than the parent compound, but their biological activity does not replicate that of free resveratrol. This mismatch is the principal reason why impressive in vitro and rodent findings have consistently failed to translate to humans.

Evidence Base

Cardiovascular Risk Markers

Sahebkar et al. 2016 meta-analysis (PMID 26975060) — 11 RCTs: Resveratrol produced statistically significant reductions in triglycerides of approximately 6.5 mg/dL and fasting glucose of 4.4 mg/dL. LDL cholesterol, HDL, CRP, and blood pressure showed no significant change. The triglyceride and glucose effects were driven almost entirely by trials enrolling patients with type 2 diabetes or metabolic syndrome; in healthy, normoglycaemic adults, no significant cardiovascular effects were observed.

2026 Umbrella Review — Ghalichi et al. (PMID 42268476): This review pooled results from 10 meta-analyses examining resveratrol in type 2 diabetes patients. The findings are sobering: across all endpoints — fasting glucose, HbA1c, insulin, HOMA-IR, HDL, triglycerides, and total cholesterol — no significant effects were found. The only statistically significant finding was a modest LDL-C reduction (SMD analysis), and insulin reduction was limited to subgroups with very large samples (n ≥ 500 and at least 10 constituent trials). Heterogeneity across studies was uniformly high. The authors explicitly conclude that resveratrol cannot be considered an effective adjunct to diabetes therapy.

Cognitive Function

Evans et al. 2017 (PMID 27789331) — systematic review of 6 RCTs: The picture is inconsistent. One trial found improvements in verbal memory tasks in postmenopausal women (n=80, 75–150 mg/day, 14 weeks). The remaining trials showed no significant effect on cognitive outcomes. Sample sizes were small (the smallest had n=12), study durations ranged from 8 to 52 weeks, and dosing protocols varied substantially. No reliable conclusions can be drawn.

Mechanistic Perspective

Baur & Sinclair 2017 (PMID 28359099) — a self-critical review by resveratrol’s most prominent proponent: Sinclair acknowledges that while the molecular targets are real (SIRT1, AMPK, PGC-1α, mTOR), translation to healthy humans remains unestablished. The doses used in animal longevity models, when extrapolated to human body weight, would substantially exceed what is commercially available. The most consistent rodent benefits are observed in obese animals on high-fat diets — whether these findings apply to lean, active humans is unknown.

What Is Not Established

• Lifespan extension in humans: No RCT has investigated or demonstrated this endpoint
• Cancer prevention: Preclinically interesting, but no valid human data
• Efficacy via dietary sources (red wine): A glass of wine contains 1–2 mg resveratrol — supplements deliver 50–500× that amount. Alcohol toxicity in wine outweighs any plausible resveratrol benefit
• Consistent cardiovascular protection in healthy adults: Not established
• Anti-aging in normal-weight individuals without metabolic disease: No RCT evidence

Dosage & Administration

Drug Interactions

• Anticoagulants (warfarin, phenprocoumon): Resveratrol inhibits platelet aggregation and CYP2C9 — bleeding risk potentially increased; consult physician before combining
• CYP3A4 substrates: Theoretical interaction; clinical relevance uncertain at typical supplemental doses
• Oestrogen-sensitive conditions: Resveratrol has weak phytoestrogenic properties — caution with oestrogen-dependent tumours or hormone-sensitive conditions

Important: At high concentrations, resveratrol may paradoxically blunt exercise-induced cardiovascular adaptations. Gliemann et al. (2013) found that resveratrol supplementation attenuated favourable training adaptations in older men — a counterintuitive finding relevant for active individuals.

EFSA Status

EFSA has approved no health claims for resveratrol. All submitted applications have been rejected for insufficient and inconsistent human evidence. Health claims such as “protects the heart,” “promotes longevity,” or “activates anti-aging genes” are not permitted on products sold in the EU.

Resveratrol from Polygonum cuspidatum (Japanese knotweed) is classified as a Novel Food in the EU and subject to corresponding authorisation requirements. Resveratrol from grape-derived extracts faces less stringent restrictions.

Safety

At standard doses (100–1,000 mg/day), resveratrol is considered well tolerated.

Known side effects:

• Gastrointestinal complaints (nausea, diarrhoea, bloating) at doses >2,000 mg/day
• Headaches occasionally reported

No serious adverse events have been identified at typical supplemental doses in short-term trials.

Summary

Resveratrol is one of the scientifically most compelling molecules in longevity research — and simultaneously one of its most consistent disappointments in translating from animal models to human trials.

The mechanisms are biologically plausible and well-established preclinically. The bioavailability problem is real and severe: less than 1% of orally ingested resveratrol reaches systemic circulation as free trans-resveratrol. Human trials show, at best, modest and inconsistent effects in metabolically compromised patient groups — and essentially nothing in healthy adults.

The most rigorous available evidence — the 2026 umbrella review of 10 meta-analyses — found no convincing effects on glucose metabolism or lipids even in type 2 diabetes patients, long considered resveratrol’s most promising target population. At this time, resveratrol supplements are not evidence-justified for healthy adults. Given its safety profile, resveratrol carries low risk, but also low demonstrated benefit for the populations most likely to purchase it.